The comparison of NASH-HCC and other HCC models
- NEWS RELEASE
Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related death in 2020.
Among them, hepatocellular carcinoma (HCC) is known to account for about 90% of all liver cancers.
Hepatitis B and C, alcohol, and diabetes are known to cause HCC, but NAFLD/NASH has been attracting attention in recent years.
Various mouse models of HCC have been established for the development of therapeutics for liver cancer.
Please find below the comparison table of our STAM™ (NASH-HCC) and other HCC models.
The STAM™ has the following features compared with other HCC models.
- shows prompt (by 20 wks of age) and definite (nearly 100%) disease development to HCC
- is non-genetic, NASH-associated cancer model that has an advantage of naturally-occurring tumor microenvironment
- allows a flexible treatment design for HCC therapeutics (preventive regimen/therapeutic regimen)
- shows HCC markers such as AFP, Glypican-3 and Glutamine synthetase, which are observed in human HCC patients.
The STAM™ model is the world's first mouse model to show the progression of NASH to liver cancer, and was developed here, at SMC Laboratories. This model shows a pathology similar to human NASH (fatty liver → NASH → liver fibrosis → HCC). Therefore, the STAM™ model has been used in many efficacy studies, as well as in basic research, and provides a wealth of basic data.
We believe that a pharmacological study using this model could help you progress with the research and development of your compound.